MedTrace Logo

A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia

NCT02595528 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 163

Last updated 2020-12-22

Study results available
· View outcomes & findings →

Summary

This study will identify the optimum concentrations of AGN-199201 and AGN-190584 when dosed in combination once a day for the improvement of uncorrected near visual acuity in participants with presbyopia (inability to focus on items close-up).

Conditions

Interventions

DRUG

AGN-199201 ophthalmic solution

1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.

DRUG

AGN-190584 ophthalmic solution

1 drop AGN-190584 ophthalmic solution doses A, B and C in the eye.

DRUG

AGN-190584 vehicle

Vehicle to AGN-190584

DRUG

AGN-199201 + AGN-190584 Combination

1 drop AGN-199201 and AGN-190584 fixed combination ophthalmic solution in the eye.

DRUG

AGN-199201 vehicle

Vehicle to AGN-199201

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Haixia Liu · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-29
Primary Completion
2017-10-18
Completion
2017-10-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02595528 on ClinicalTrials.gov